# Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL

> **NCT05559450** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 80 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Blinatumomab
- **OTHER:** Conventional therapy

## Key facts

- **NCT ID:** NCT05559450
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2026-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-09-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05559450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05559450, "Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05559450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*